#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism


Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly. The virus-host interactions that governed development of these acute end stage lung diseases and death are unknown. To address this question, we evaluated the role of innate immune signaling in protection from human (Urbani) and a recombinant mouse adapted SARS-CoV, designated rMA15. In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice. This suggests that type I, II and III interferon signaling play minor roles in regulating SARS pathogenesis in mouse models. In contrast, infection of STAT1−/− mice resulted in severe disease, high virus titer, extensive pulmonary lesions and 100% mortality by day 9 and 30 post-infection with rMA15 or Urbani viruses, respectively. Non-lethal in BALB/c mice, Urbani SARS-CoV infection in STAT1−/− mice caused disseminated infection involving the liver, spleen and other tissues after day 9. These findings demonstrated that SARS-CoV pathogenesis is regulated by a STAT1 dependent but type I, II and III interferon receptor independent, mechanism. In contrast to a well documented role in innate immunity, we propose that STAT1 also protects mice via its role as an antagonist of unrestrained cell proliferation.


Vyšlo v časopise: SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism. PLoS Pathog 6(4): e32767. doi:10.1371/journal.ppat.1000849
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000849

Souhrn

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly. The virus-host interactions that governed development of these acute end stage lung diseases and death are unknown. To address this question, we evaluated the role of innate immune signaling in protection from human (Urbani) and a recombinant mouse adapted SARS-CoV, designated rMA15. In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice. This suggests that type I, II and III interferon signaling play minor roles in regulating SARS pathogenesis in mouse models. In contrast, infection of STAT1−/− mice resulted in severe disease, high virus titer, extensive pulmonary lesions and 100% mortality by day 9 and 30 post-infection with rMA15 or Urbani viruses, respectively. Non-lethal in BALB/c mice, Urbani SARS-CoV infection in STAT1−/− mice caused disseminated infection involving the liver, spleen and other tissues after day 9. These findings demonstrated that SARS-CoV pathogenesis is regulated by a STAT1 dependent but type I, II and III interferon receptor independent, mechanism. In contrast to a well documented role in innate immunity, we propose that STAT1 also protects mice via its role as an antagonist of unrestrained cell proliferation.


Zdroje

1. DonnellyCA

GhaniAC

LeungGM

HedleyAJ

FraserC

2003 Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361 1761 1766

2. DrostenC

GuntherS

PreiserW

van der WerfS

BrodtHR

2003 Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 1967 1976

3. LevyDE

Garcia-SastreA

2001 The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 12 143 156

4. SethRB

SunL

ChenZJ

2006 Antiviral innate immunity pathways. Cell Res 16 141 147

5. TakaokaA

YanaiH

2006 Interferon signalling network in innate defence. Cell Microbiol 8 907 922

6. RymanKD

WhiteLJ

JohnstonRE

KlimstraWB

2002 Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol 15 53 76

7. DurbinJE

JohnsonTR

DurbinRK

MertzSE

MorottiRA

2002 The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 168 2944 2952

8. JohnsonTR

MertzSE

GitibanN

HammondS

LegalloR

2005 Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 174 7234 7241

9. KellerBC

FredericksenBL

SamuelMA

MockRE

MasonPW

2006 Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80 9424 9434

10. DurbinJE

HackenmillerR

SimonMC

LevyDE

1996 Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 443 450

11. BrayM

2001 The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82 1365 1373

12. DurbinJE

Fernandez-SesmaA

LeeCK

RaoTD

FreyAB

2000 Type I IFN modulates innate and specific antiviral immunity. J Immunol 164 4220 4228

13. BaslerCF

WangX

MuhlbergerE

VolchkovV

ParagasJ

2000 The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97 12289 12294

14. ReidSP

LeungLW

HartmanAL

MartinezO

ShawML

2006 Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80 5156 5167

15. SalvatoreM

BaslerCF

ParisienJP

HorvathCM

BourmakinaS

2002 Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol 76 1206 1212

16. YuanW

KrugRM

2001 Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. Embo J 20 362 371

17. RodriguezJJ

ParisienJP

HorvathCM

2002 Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 76 11476 11483

18. FriemanM

YountB

HeiseM

Kopecky-BrombergSA

PaleseP

2007 Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81 9812 9824

19. Kopecky-BrombergSA

Martinez-SobridoL

FriemanM

BaricRA

PaleseP

2007 Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81 548 557

20. WatheletMG

OrrM

FriemanMB

BaricRS

2007 Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 81 11620 11633

21. ZhaoJ

FalconA

ZhouH

NetlandJ

EnjuanesL

2009 Severe acute respiratory syndrome coronavirus protein 6 is required for optimal replication. J Virol 83 2368 2373

22. CameronMJ

RanL

XuL

DaneshA

Bermejo-MartinJF

2007 Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81 8692 8706

23. RockxB

BaasT

ZornetzerGA

HaagmansB

SheahanT

2009 Early Upregulation of ARDS Associated Cytokines Promote Lethal Disease in an Aged Mouse Model of SARS-CoV Infection. J Virol

24. BaasT

RobertsA

TealTH

VogelL

ChenJ

2008 Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J Virol 82 9465 9476

25. HaynesLM

MooreDD

Kurt-JonesEA

FinbergRW

AndersonLJ

2001 Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75 10730 10737

26. SheahanT

MorrisonTE

FunkhouserW

UematsuS

AkiraS

2008 MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4 e1000240 doi:10.1371/journal.ppat.1000240

27. HallerO

ArnheiterH

GresserI

LindenmannJ

1981 Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. J Exp Med 154 199 203

28. GlassWG

SubbaraoK

MurphyB

MurphyPM

2004 Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173 4030 4039

29. HoganRJ

GaoG

RoweT

BellP

FliederD

2004 Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol 78 11416 11421

30. RobertsA

DemingD

PaddockCD

ChengA

YountB

2007 A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice. PLoS Pathog 3 e5 doi:10.1371/journal.ppat.0030005

31. LoAW

TangNL

ToKF

2006 How the SARS coronavirus causes disease: host or organism? J Pathol 208 142 151

32. HwangDM

ChamberlainDW

PoutanenSM

LowDE

AsaSL

2005 Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 18 1 10

33. PaulNS

RobertsH

ButanyJ

ChungT

GoldW

2004 Radiologic pattern of disease in patients with severe acute respiratory syndrome: the Toronto experience. Radiographics 24 553 563

34. KetaiL

PaulNS

WongKT

2006 Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease. J Thorac Imaging 21 276 283

35. RobertsA

PaddockC

VogelL

ButlerE

ZakiS

2005 Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79 5833 5838

36. SubbaraoK

McAuliffeJ

VogelL

FahleG

FischerS

2004 Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78 3572 3577

37. KotenkoSV

GallagherG

BaurinVV

Lewis-AntesA

ShenM

2003 IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 69 77

38. SchindlerC

DarnellJEJr

1995 Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64 621 651

39. KoernerI

KochsG

KalinkeU

WeissS

StaeheliP

2007 Protective role of beta interferon in host defense against influenza A virus. J Virol 81 2025 2030

40. GerlachN

SchimmerS

WeissS

KalinkeU

DittmerU

2006 Effects of type I interferons on Friend retrovirus infection. J Virol 80 3438 3444

41. KussSK

EtheredgeCA

PfeifferJK

2008 Multiple host barriers restrict poliovirus trafficking in mice. PLoS Pathog 4 e1000082 doi:10.1371/journal.ppat.1000082

42. KatzeMG

HeY

GaleMJr

2002 Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2 675 687

43. WaltersDM

Antao-MenezesA

IngramJL

RiceAB

NyskaA

2005 Susceptibility of signal transducer and activator of transcription-1-deficient mice to pulmonary fibrogenesis. Am J Pathol 167 1221 1229

44. Antao-MenezesA

TurpinEA

BostPC

Ryman-RasmussenJP

BonnerJC

2008 STAT-1 signaling in human lung fibroblasts is induced by vanadium pentoxide through an IFN-beta autocrine loop. J Immunol 180 4200 4207

45. BrombergJ

DarnellJEJr

2000 The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 2468 2473

46. FrankDA

1999 STAT signaling in the pathogenesis and treatment of cancer. Mol Med 5 432 456

47. KlampferL

2006 Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6 107 121

48. LevitzkiA

MishaniE

2006 Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75 93 109

49. YoonP

KeylockKT

HartmanME

FreundGG

WoodsJA

2004 Macrophage hypo-responsiveness to interferon-gamma in aged mice is associated with impaired signaling through Jak-STAT. Mech Ageing Dev 125 137 143

50. LauYL

PeirisJS

2005 Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 17 404 410

51. FriemanM

RatiaK

JohnstonRE

MesecarAD

BaricRS

2009 Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83 6689 6705

52. NichollsJM

ButanyJ

PoonLL

ChanKH

BehSL

2006 Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med 3 e27 doi:10.1371/journal.pmed.0030027

53. Chan-YeungM

XuRH

2003 SARS: epidemiology. Respirology 8 Suppl S9 14

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2010 Číslo 4
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#